These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 37888583)

  • 21. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies.
    Yu X; Zhu L; Wang T; Chen J
    Front Immunol; 2023; 14():1037945. PubMed ID: 37138880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Zimmer CL; Filipovic I; Cornillet M; O'Rourke CJ; Berglin L; Jansson H; Sun D; Strauss O; Hertwig L; Johansson H; von Seth E; Sparrelid E; Dias J; Glaumann H; Melum E; Ellis EC; Sandberg JK; Andersen JB; Bergquist A; Björkström NK
    Hepatology; 2022 May; 75(5):1154-1168. PubMed ID: 34719787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
    Ruff SM; Shannon AH; Pawlik TM
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Functional Roles of Immune Cells in Primary Liver Cancer.
    Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
    Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of tumour microenvironment: a new vision for cholangiocarcinoma.
    Chen Z; Guo P; Xie X; Yu H; Wang Y; Chen G
    J Cell Mol Med; 2019 Jan; 23(1):59-69. PubMed ID: 30394682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.
    Cao Z; Zeng L; Wang Z; Wen X; Zhang J
    Funct Integr Genomics; 2023 May; 23(2):190. PubMed ID: 37247093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review.
    Elvevi A; Laffusa A; Gallo C; Invernizzi P; Massironi S
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunology and immunotherapy of cholangiocarcinoma.
    Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
    Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Insight into Cholangiocarcinoma and Recent Advances in its Treatment.
    Sahu R; Sharma P; Kumar A
    J Gastrointest Cancer; 2023 Mar; 54(1):213-226. PubMed ID: 35023010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteogenomic characterization of cholangiocarcinoma.
    Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
    Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
    Louis C; Edeline J; Coulouarn C
    Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
    Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
    Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
    Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
    J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment.
    Shi A; Liu Z; Fan Z; Li K; Liu X; Tang Y; Hu J; Li X; Shu L; Zhao L; Huang L; Zhang Z; Lv G; Zhang Z; Xu Y
    Gut; 2024 Jul; 73(8):1350-1363. PubMed ID: 38458750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
    Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
    Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.